LifeSci Capital Initiates Coverage of Theraclion

Non-Invasive, CE Marked Instrument for Breast Fibroadenomas and Thyroid Nodules; Report Available here: www.lifescicapital.com/equity-research/theraclion/

NEW YORK, NY / ACCESSWIRE / July 7, 2015 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Theraclion (Euronext: ALTHE.PA), a commercial-stage company that markets the Echopulse, a non-invasive instrument for the treatment of breast fibroadenomas and thyroid nodules. The device is already on the market in Europe, and the Company is pursuing approval in the US and China. Echopulse is currently the only non-invasive therapy for breast fibroadenomas and thyroid nodules with no incision or requirement for general anesthesia.

Theraclion’s Echopulse is an ultrasound-guided device that uses high-intensity focused ultrasound (HIFU) waves to selectively kill tumor cells without affecting healthy tissue. The instrument is CE marked for breast fibroadenomas and thyroid nodules in the EU and is currently being sold in select countries where CE marking is accepted. A total of 12 devices have been sold or installed to date. It is the only completely non-invasive solution for its target indications and could address a market that exceeds 900,000 patients per year in the EU, US, and China. Theraclion has initiated clinical studies in the US and is laying the groundwork in China to seek regulatory approval in these countries. Additional studies are also underway to potentially expand the Echopulse into indications that represent additional, large market opportunities.

In a 26 page Initiation Report LifeSci Capital explains the commercialization pathway and market potential for Echopulse. The report also discusses plans to expand Echopulse into the US and Chinese markets.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Theraclion as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital

ReleaseID: 430403